RNA vaccine - Orlance
Latest Information Update: 22 Jul 2024
At a glance
- Originator Orlance
- Class Cancer vaccines; COVID-19 vaccines; Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; COVID 2019 infections; Influenza virus infections
Most Recent Events
- 10 Jul 2024 Orlance receives SBIR Phase I grant from National Institutes of Health for development of RNA vaccine formulations usingneedle-free MACH-1™ platform
- 10 Jul 2024 Preclinical trials in Cancer in USA (Intradermal) before July 2024
- 10 Jul 2024 Preclinical trials in COVID-2019 infections in USA (Intradermal) before July 2024